ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial
At the European Respiratory Society (ERS) Congress 2026, investigators from AstraZeneca and collaborating institutions presented the company's Phase IIb PRESTO…
At the European Respiratory Society (ERS) Congress 2026, investigators from AstraZeneca and collaborating institutions presented the company's Phase IIb PRESTO…